TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells.

Cui, Zhilei; Liu, Zhen; Zeng, Junxiang; Zhang, Shulin; Chen, Lei; Zhang, Guorui; Xu, Weiguo; Song, Lin; Guo, Xuejun

Cui, Zhilei; Liu, Zhen; Zeng, Junxiang; Zhang, Shulin; Chen, Lei; Zhang, Guorui; Xu, Weiguo; Song, Lin; Guo, Xuejun.

Afiliação

Cui Z; Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China.
Liu Z; State Key Laboratory of Microbial Metabolism, School of Life Science and Biotechnology, Shanghai Jiao Tong University, China.
Zeng J; Department of Laboratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China.
Zhang S; Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, China.
Chen L; Department of Pathology, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China.
Zhang G; Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China.
Xu W; Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China.
Song L; Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China. Electronic address: everlasting1981@126.com.
Guo X; Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China. Electronic address: guoxuejun@xinhuamed.com.cn.

Life Sci ; 224: 23-32, 2019 May 01.

Article em En | MEDLINE | ID: mdl-30902544

Assuntos

Adenocarcinoma/patologia; Resistencia a Medicamentos Antineoplásicos/genética; Gefitinibe/farmacologia; Neoplasias Pulmonares/patologia; Proteínas de Membrana/metabolismo; Metaloproteínas/metabolismo; Mutação; Adenocarcinoma/tratamento farmacológico; Adenocarcinoma/genética; Adenocarcinoma/metabolismo; Antineoplásicos/farmacologia; Apoptose/efeitos dos fármacos; Proliferação de Células/efeitos dos fármacos; Receptores ErbB/genética; Humanos; Peptídeos e Proteínas de Sinalização Intracelular; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/metabolismo; Proteínas de Membrana/genética; Metaloproteínas/genética; Fator de Transcrição STAT3/metabolismo; Transdução de Sinais; Proteínas com Motivo Tripartido; Células Tumorais Cultivadas

Palavras-chave

Gefitinib resistance; Non-small-cell lung cancer; Phosphorylation; STAT3; TRIM59

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Resistencia a Medicamentos Antineoplásicos / Gefitinibe / Neoplasias Pulmonares / Proteínas de Membrana / Metaloproteínas / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Life Sci Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google